Ion Arocena, CEO of ASEBIO, Spain’s biotech association, discusses the significant efforts that Spain has made in turning cutting-edge research into successful companies and products and provides an insight into the level of collaboration and interaction between all stakeholders across the whole healthcare ecosystem.
Can you provide us a with a full picture of the biotech sector in Spain in terms of growth dynamics, strengths and weaknesses of the sector?
" We have good science, good start-ups and outstanding talent. In my view, what is missing is long-term stable policies. Spain has identified certain incentives for R&D activities, but the structure of such incentives can be definitely improved because most of the money that companies receive are simply soft loans in the guise of ‘grants’."
